Related references
Note: Only part of the references are listed.Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients with Prediabetes
Alejandra M. Ramirez-Rodriguez et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2020)
Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs
Awadhesh Kumar Singh et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2020)
Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials
David M. Williams et al.
DIABETES THERAPY (2020)
A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials
Joachim Tillner et al.
DIABETES OBESITY & METABOLISM (2019)
Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity
Maria J. Pereira et al.
DRUGS (2019)
Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities
Emily Brown et al.
OBESITY REVIEWS (2019)
Comparative Efficacy of Bariatric Surgery in the Treatment of Morbid Obesity and Diabetes Mellitus: a Systematic Review and Network Meta-Analysis
Chan Hyuk Park et al.
OBESITY SURGERY (2019)
Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
Richard Pratley et al.
LANCET (2019)
SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into Practice
Amar Ali et al.
DIABETES THERAPY (2019)
Medical Devices in Obesity Treatment
Aruchuna Ruban et al.
CURRENT DIABETES REPORTS (2019)
The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion-A Review
David S. Mathiesen et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity
Ryota Usui et al.
JOURNAL OF DIABETES INVESTIGATION (2019)
Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss in Obese Humans With and Without Type 2 Diabetes
Sudha S. Shankar et al.
DIABETES (2018)
Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in a NASH and Fibrosis Animal Model
In Young Choi et al.
DIABETES (2018)
Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial
Richard E. Pratley et al.
DIABETES OBESITY & METABOLISM (2018)
Are peptide conjugates the golden therapy against obesity?
S. J. Brandt et al.
JOURNAL OF ENDOCRINOLOGY (2018)
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
Philip Ambery et al.
LANCET (2018)
Oxyntomodulin analogue increases energy expenditure via the glucagon receptor
R. Scott et al.
PEPTIDES (2018)
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
Richard E. Pratley et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Recent updates on GLP-1 agonists: Current advancements & challenges
Dilip Sharma et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
Patrick M. O'Neil et al.
LANCET (2018)
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Juan Pablo Frias et al.
LANCET (2018)
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
Tamer Coskun et al.
MOLECULAR METABOLISM (2018)
Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study
Samuel Dagogo-Jack et al.
DIABETES OBESITY & METABOLISM (2018)
Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25
Debbie L. Hay et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
Pharmacokinetics and pharmacodynamics of PF-05190457: The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects
William S. Denney et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes
Per Lundkvist et al.
DIABETES OBESITY & METABOLISM (2017)
Health Effects of Overweight and Obesity in 195 Countries over 25 Years
Ashkan Afshin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effect of orlistat on plasma lipids and body weight: A systematic review and meta-analysis of 33 randomized controlled trials
Amirhossein Sahebkar et al.
PHARMACOLOGICAL RESEARCH (2017)
Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency
Tinh-Hai Collet et al.
MOLECULAR METABOLISM (2017)
Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice
Sigrid Jall et al.
MOLECULAR METABOLISM (2017)
GLP-1/glucagon receptor co-agonism for treatment of obesity
Miguel A. Sanchez-Garrido et al.
DIABETOLOGIA (2017)
Re-visiting the Endocannabinoid System and Its Therapeutic Potential in Obesity and Associated Diseases
Joyce M. Richey et al.
CURRENT DIABETES REPORTS (2017)
Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year
Per Lundkvist et al.
DIABETES OBESITY & METABOLISM (2017)
Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial
Priscilla Hollander et al.
DIABETES CARE (2017)
A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference
Sofie Gydesen et al.
BRITISH JOURNAL OF PHARMACOLOGY (2017)
Liraglutide for weight management: a critical review of the evidence
A. Mehta et al.
OBESITY SCIENCE & PRACTICE (2017)
Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy
Cristina Adelia Meehan et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2016)
Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist
Peter Kuehnen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Caroline M Apovian et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
European Guidelines for Obesity Management in Adults
Volkan Yumuk et al.
OBESITY FACTS (2015)
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Brian Finan et al.
NATURE MEDICINE (2015)
Cost-Effectiveness Analysis of Qsymia for Weight Loss
Eric A. Finkelstein et al.
PHARMACOECONOMICS (2015)
The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis
Jessica E. Potts et al.
PLOS ONE (2015)
Amylin: Pharmacology, Physiology, and Clinical Potential
Debbie L. Hay et al.
PHARMACOLOGICAL REVIEWS (2015)
A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts antiobesity and antidiabetic effects in rats
Kim V. Andreassen et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2014)
Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Hans-Ulrich Haering et al.
DIABETES CARE (2014)
Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)
Guillermo Umpierrez et al.
DIABETES CARE (2014)
Canagliflozin: Effects in Overweight and Obese Subjects Without Diabetes Mellitus
Harold E. Bays et al.
OBESITY (2014)
Meta- and Cost-Effectiveness Analysis of Commercial Weight Loss Strategies
Eric A. Finkelstein et al.
OBESITY (2014)
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
Martin Ridderstrale et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
The Clinical Development Program of Lixisenatide: A Once-Daily Glucagon-Like Peptide-1 Receptor Agonist
Stephen C. Bain
DIABETES THERAPY (2014)
Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
Clifford J. Bailey et al.
BMC MEDICINE (2013)
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
K. Stenlof et al.
DIABETES OBESITY & METABOLISM (2013)
Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
T. A. Wadden et al.
INTERNATIONAL JOURNAL OF OBESITY (2013)
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
William T. Cefalu et al.
LANCET (2013)
Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs
E. W. Chan et al.
OBESITY REVIEWS (2013)
Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials
Viktoria L. Gloy et al.
BMJ-BRITISH MEDICAL JOURNAL (2013)
A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials
Giovanni Musso et al.
ANNALS OF MEDICINE (2012)
Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review
Vanita R. Aroda et al.
CLINICAL THERAPEUTICS (2012)
Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)
Vivian A. Fonseca et al.
DIABETES CARE (2012)
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
A. Astrup et al.
INTERNATIONAL JOURNAL OF OBESITY (2012)
The medical care costs of obesity: An instrumental variables approach
John Cawley et al.
JOURNAL OF HEALTH ECONOMICS (2012)
Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus
Chrysi Koliaki et al.
Diabetes Therapy (2011)
Narrative Review: The Role of Leptin in Human Physiology: Emerging Clinical Applications
Theodore Kelesidis et al.
ANNALS OF INTERNAL MEDICINE (2010)
Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise A randomized, double-blind, placebo-controlled, phase 3 trial
Ele Ferrannini et al.
DIABETES CARE (2010)
Enhanced Weight Loss Following Coadministration of Pramlintide With Sibutramine or Phentermine in a Multicenter Trial
Louis J. Aronne et al.
OBESITY (2010)
New central targets for the treatment of obesity
Bruce J. Sargent et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
James F. List et al.
DIABETES CARE (2009)
Enhanced Weight Loss With Pramlintide/Metreleptin: An Integrated Neurohormonal Approach to Obesity Pharmacotherapy
Eric Ravussin et al.
OBESITY (2009)
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Robin Christensen et al.
LANCET (2007)
Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss
William P. Esler et al.
ENDOCRINOLOGY (2007)
Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: A phase 2, randomized, placebo-controlled, dose-escalation study
Louis Aronne et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Biology of incretins: GLP-1 and GIP
Laurie L. Baggio et al.
GASTROENTEROLOGY (2007)
Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor
I. Sadaf Farooqi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial
K. Wynne et al.
INTERNATIONAL JOURNAL OF OBESITY (2006)
Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults
Ngozi Erondu et al.
CELL METABOLISM (2006)
Vaccination against weight gain
Eric P. Zorrilla et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
JP Despres et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects - A double-blind, randomized, controlled trial
K Wynne et al.
DIABETES (2005)
Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes
I Chapman et al.
DIABETOLOGIA (2005)
Peripheral oxyntomodulin reduces food intake and body weight gain in rats
CL Dakin et al.
ENDOCRINOLOGY (2004)
Oxyntomodulin suppresses appetite and reduces food intake in humans
MA Cohen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Share Paper
